Response Genetics, Inc. , a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, today announced that it has signed agreements with two new Blue Cross Blue Shield health plans.
Response Genetics’ new Blue Cross Blue Shield contracts are with:
- Blue Cross and Blue Shield of Minnesota
- Blue Cross and Blue Shield of Nebraska
These partnerships mark another leap forward in Response Genetics’ growing managed care contracting program. With these additional agreements, Response Genetics is now in-network with a total of eight Blue Cross Blue Shield health plans. Among Response Genetics’ other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).
Response Genetics’ molecular testing primarily focuses on patients suffering from lung, colon, gastric and melanoma cancers. Response Genetics’ menu of genomic assays gives treating physicians actionable information on a patient’s tumor and which course of therapy will work best for that patient. Response Genetics’ participation with these Blues plans should improve plan members’ access to individually-tailored medicine.
Date: December 18, 2013